MalarVX Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 6


  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $217K

  • Investors
  • 3

MalarVX General Information


Operator of a biopharmaceutical company intended to help eradicate both falciparum and vivax malaria from the world. The company is focused on the development of in vitro culture systems for the malaria parasite which will lead to the development of an effective whole-parasite vaccine, providing the medical industry with a safe, effective, and affordable malaria vaccine.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Corporate Office
  • 1551 Eastlake Avenue East
  • Suite 100
  • Seattle, WA 98102-3788
  • United States
+1 (206) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MalarVX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 21-Sep-2020 $217K 00.00 Completed Startup
4. Grant 01-Jan-2019 00000 00.00 Completed Startup
3. Grant 01-Jan-2019 00000 00.00 Completed Startup
2. Seed Round 21-Jun-2017 $1.05M $1.8M Completed Startup
1. Angel (individual) 23-Nov-2015 $750K $750K Completed Startup
To view MalarVX’s complete valuation and funding history, request access »

MalarVX Executive Team (2)

Name Title Board Seat Contact Info
Paul Harris Ph.D Co-Founder & Vice President, Product Development
James Davie President & Chief Executive Officer
To view MalarVX’s complete executive team members history, request access »

MalarVX Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MalarVX Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
Keiretsu Forum Angel Group Minority 000 0000 000000 0
To view MalarVX’s complete investors history, request access »

MalarVX FAQs

  • When was MalarVX founded?

    MalarVX was founded in 2012.

  • Who is the founder of MalarVX?

    Paul Harris Ph.D is the founder of MalarVX.

  • Who is the CEO of MalarVX?

    James Davie is the CEO of MalarVX.

  • Where is MalarVX headquartered?

    MalarVX is headquartered in Seattle, WA.

  • What is the size of MalarVX?

    MalarVX has 6 total employees.

  • What industry is MalarVX in?

    MalarVX’s primary industry is Drug Discovery.

  • Is MalarVX a private or public company?

    MalarVX is a Private company.

  • What is MalarVX’s current revenue?

    The current revenue for MalarVX is 00000.

  • How much funding has MalarVX raised over time?

    MalarVX has raised $1.8M.

  • Who are MalarVX’s investors?

    National Institutes of Health, United States Department of Defense, and Keiretsu Forum have invested in MalarVX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »